NeuroSense Therapeutics Ltd. (NRSN) Earnings History
Annual and quarterly earnings data from 2019 to 2024
Loading earnings history...
NRSN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
NRSN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
Download Data
Export NRSN earnings history in CSV or JSON format
Free sign-in required to download data
NeuroSense Therapeutics Ltd. (NRSN) Earnings Overview
As of May 8, 2026, NeuroSense Therapeutics Ltd. (NRSN) reported trailing twelve-month net income of -$9M, reflecting +33.7% year-over-year growth. The company earned $-0.34 per diluted share over the past four quarters.
Looking at the long-term picture, NRSN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$1M in fiscal 2019.
NeuroSense Therapeutics Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRTA (-$151M net income, -2520.6% margin), ACIU (-$70M net income, -1971.6% margin), SAVA (-$106M net income), NRSN has comparable earnings metrics. Compare NRSN vs PRTA →
NRSN Earnings vs Peers
Earnings metrics vs comparable public companies
NRSN Historical Earnings Data (2019–2024)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$10M | -1.0% | -$10M | $-0.55 | - | - |
| 2023 | -$10M | +18.1% | -$12M | $-0.83 | - | - |
| 2022 | -$12M | -205.4% | -$14M | $-1.07 | - | - |
| 2021 | -$4M | -42.9% | -$6M | $-0.23 | - | - |
| 2020 | -$3M | -130.5% | -$3M | $-0.51 | - | - |
| 2019 | -$1M | - | -$1M | $-0.22 | - | - |
See NRSN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NRSN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NRSN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNRSN — Frequently Asked Questions
Quick answers to the most common questions about buying NRSN stock.
Is NRSN growing earnings?
NRSN EPS is $-0.34, with earnings growth accelerating to +33.7%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-9M.
What are NRSN's profit margins?
NeuroSense Therapeutics Ltd. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are NRSN's earnings?
NRSN earnings data spans 2019-2024. The accelerating earnings trend is +33.7% YoY. Historical data enables comparison across business cycles.